Intervention

ADT

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 32 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials32

Recruiting9

Common conditions25

Lead sponsors shown15

Clinical trials

32 shown

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT TreatmentNCT07538843 · 2026-07-31

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.NCT07450599 · 2026-04-27

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)NCT07210086 · 2025-11-26

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerNCT05873192 · 2025-06-03

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate TreatmentNCT06235697 · 2024-04-25

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate CancerNCT04633252 · 2021-02-23

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerNCT05406999 · 2020-02-01

National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer PatientsNCT04086290 · 2019-10-10

Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.NCT07730151 · 2026-08-01

NOT_YET_RECRUITING

A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical PracticeNCT07344779 · 2026-01-29

ACTIVE_NOT_RECRUITING

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNCT05849298 · 2024-01-03

ACTIVE_NOT_RECRUITING

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + AbirateroneNCT06060587 · 2023-10-19

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906 · 2023-04-03

ACTIVE_NOT_RECRUITING

Tracer-Guided Surgery for Recurrent Prostate CancerNCT05555017 · 2023-02-15

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate CancerNCT04599686 · 2022-09-11

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.NCT05059236 · 2021-11-04

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)NCT04720157 · 2021-06-09

ACTIVE_NOT_RECRUITING

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for MetastasesNCT04523207 · 2020-08-19

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation TherapyNCT03496805 · 2019-01-29

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy RadiotherapyNCT03388619 · 2018-01-17

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate CancerNCT02972060 · 2017-12-01

ACTIVE_NOT_RECRUITING

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone LevelsNCT02867020 · 2017-10-11

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant TreatmentNCT02400346 · 2015-03-01

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive TherapyNCT02012218 · 2013-11-01

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentNCT01838681 · 2013-06-01

The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic CancerNCT01487902 · 2010-07-01

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive DisorderNCT01052077 · 2010-03-01

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive DisorderNCT01447576 · 2009-09-01

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT00797966 · 2009-05-01

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate CancerNCT00658697 · 2008-06-01

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyNCT00268476 · 2005-07-08

ACTIVE_NOT_RECRUITING

Common conditions

Leading sponsors

Bayer 5 Otsuka Pharmaceutical Development & Commercialization, Inc. 4 Canadian Cancer Trials Group 2 H. Lundbeck A/S 2 National Cancer Institute (NCI) 2 Novartis Pharmaceuticals 2 Asan Medical Center 1 Changhai Hospital 1 City of Hope Medical Center 1 Dana-Farber Cancer Institute 1 European Organisation for Research and Treatment of Cancer - EORTC 1 Janssen Research & Development, LLC 1 Latin American Cooperative Oncology Group 1 M.D. Anderson Cancer Center 1 Medical Research Council 1

Trial status mix

COMPLETED12

RECRUITING9

ACTIVE_NOT_RECRUITING6

UNKNOWN3

NOT_YET_RECRUITING1

WITHDRAWN1

Phase mix

PHASE221

PHASE38

PHASE13

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.